earn report chang price
think insid servic
sequenc consum grew w/ demand mostli due
novaseq also due strength nextseq clinic market
high throughput consum growth came better
novaseq consum growth ex mm sotck order
sequenti
array continu strong driven growth geneolog
guidanc appear overli conserv continu
outperform nextseq fire
expect lower sequenti due mix array growth
thesi updat investor need start pivot think
judg quarter think manag also tri
lead conclus box placement alon
anymor isnt product cycl massiv inflect
sequenc demand unlik anyth seen quit
time end market perspect term breadth like
never seen clinic real drive materi upsid
hello liquid biopsi welcom parti beat came
consum servic essenti thing
degre servic arent warranti sale consum
process lab expans also
best indic underli demand box placement
go placement go outsid histor base high
end expans consum per box key instrument
high end histor rang acceler term novaseq
expans obviou conclus demand
fire box placement continu capac util
run hot across key instrument super
posit long term investor nitpick guid magnitud
rais end day number move much higher
stock one best open end growth stori
market rais fy high-end guid dont
mad jacqui take year estim notabl
pt move higher upsid see
stock go time buy stock tomorrow hand
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
 rais due higher sequenc consum array increas forecast sequenc consum
mileston payment recent oncolog collabor
 maintain shipment
 maintain expect slightli
 opex slightli higher sale
 rais due higher revenu
 tax tw helix dilut ex-tax benefit
 modest sequenti growth sequenc consum growth partial off-set season declin array
 sequenti due mix
 opex line histor run-rat sale
high throughput consum mm vs mm
sequenc consum qoq declin came better expect
 yoy growth came better st management expect vs due strength nipt high throughput
strength nextseq pull-through come high end
elev pull-through rate nextseq emerg workhors box clinic market lot clinic demand show
nextseq side
 nipt growth continu robust gain traction ou netherland adopt program veriseq expect doubl
see robust demand clinic custom manag call wg demand kid rugd undiagnos
popul genom continu help drive growth genom england genom expect complet
end year
 plan use wg rare dx cancer
dtc go robust grant fda approv brca test
new sequenc custom account benchtop shipment
nextseq instrument growth partli due rapid uptak clinic oncolog applic
iseq beta start ship still plan roll-out mid-year
shipment hiseq custom custom
expect fleet replac start end
order new-to-ilmn sequenc benchtop sequenc
expect shipment measur upgrad cycl play yr
million except per share data fy end decemb sequenc organ gp less op less ep share inc net inc price-to-earnings prem disc april
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin april et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
